XL BCR/ABL1 plus

Translocation/Dual Fusion Probe

Order Number
Package Size
100 µl (10 Tests)


XL BCR/ABL1 plus

The XL BCR/ABL1 plus probe is specific for the t(9;22). The orange labeled probe hybridizes to an extended region spanning the ABL1 locus on 9q34, and a green labeled probe hybridizes specifically to extended regions spanning the BCR gene on 22q11. The probe is designed as a dual-color, dual-fusion assay.

Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale.

Need Help?

Clinical Details

Chronic myelogenous leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22, called the Philadelphia (Ph) chromosome. The same translocation can also be found in acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) with some variation in the breakpoint region. Glivec® (imatinib mesylate) treatment targeting the BCR/ABL active tyrosine kinase has become a major drug in treating CML, gastrointestinal stromal tumors, and other cancers.

Clinical Applications

  • Chronic Myelogenous Leukemia and Myeloproliferative Neoplasms (CML/MPN)
  • Acute Lymphoblastic Leukemia (ALL)
  • Acute Myelogenous Leukemia (AML)
Need Help?


XL BCR/ABL1 plus

XL BCR/ABL1 plus hybridized to bone marrow cells. Two interphase cells with two fusion signals and separated orange and green signals each are shown, indicating a BCR/ABL1 translocation.

Need Help?

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange signals (2O).

Expected Pattern 2

Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange fusion signals (2GO).

Need Help?


  • Dewald et al (1998) Blood 91:3357-3365
  • Huntly et al (2003) Blood 102:1160-1168
  • Primo et al (2003) Leukemia 17:1124-1129